Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1150 ARTÍCULOS , VIENDO DEL 1081 AL 1095

Loss of serotonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer's disease: a combined [11C]DASB and [18F]altanserin-PET study

Marner L, Frokjaer VG, Kalbitzer J, Lehel S, Madsen K, Baaré WF, Knudsen GM, Hasselbalch SG.

Neurobiol Aging. 2012 Mar;33(3):479-87. doi: 10.1016/j.neurobiolaging.2010.03.023. Epub 2010 May 26.

Association of CLU and PICALM variants with Alzheimer's disease

Kamboh MI, Minster RL, Demirci FY, Ganguli M, Dekosky ST, Lopez OL, Barmada MM.

Neurobiol Aging. 2012 Mar;33(3):518-21. doi: 10.1016/j.neurobiolaging.2010.04.015. Epub 2010 Jun 8.

The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE

Guerreiro RJ, Gustafson DR, Hardy J.

Neurobiol Aging. 2012 Mar;33(3):437-56. doi: 10.1016/j.neurobiolaging.2010.03.025. Epub 2010 Jul 1.

Association and heterogeneity at the GAPDH locus in Alzheimer's disease

Allen M, Cox C, Belbin O, Ma L, Bisceglio GD, Wilcox SL, Howell CC, Hunter TA, Culley O, Walker LP, Carrasquillo MM, Dickson DW, Petersen RC, Graff-Radford NR, Younkin SG, Ertekin-Taner N.

Neurobiol Aging. 2012 Jan;33(1):203.e25-33. doi: 10.1016/j.neurobiolaging.2010.08.002. Epub 2010 Sep 23.

Validation of the neurobehavioral cognitive status examination and the Rivermead Behavioural Memory Test in investigations of dementia

Johansson M, Wressle E.

Scand J Occup Ther. 2012 May;19(3):282-7. doi: 10.3109/11038128.2010.528789. Epub 2010 Nov 25.

Early and late onset Alzheimer's disease patients have distinct patterns of white matter damage

Canu E, Frisoni GB, Agosta F, Pievani M, Bonetti M, Filippi M.

Neurobiol Aging. 2012 Jun;33(6):1023-33. doi: 10.1016/j.neurobiolaging.2010.09.021. Epub 2010 Nov 12.

Diagnostic power of default mode network resting state fMRI in the detection of Alzheimer's disease

Koch W, Teipel S, Mueller S, Benninghoff J, Wagner M, Bokde AL, Hampel H, Coates U, Reiser M, Meindl T.

Neurobiol Aging. 2012 Mar;33(3):466-78. doi: 10.1016/j.neurobiolaging.2010.04.013. Epub 2010 Jun 11.

Contribution of brain imaging to the understanding of gait disorders in Alzheimer's disease: a systematic review

Annweiler C, Beauchet O, Celle S, Roche F, Annweiler T, Allali G, Bartha R, Montero-Odasso M; WALK Team (Working group Angers-London for Knowledge).

Am J Alzheimers Dis Other Demen. 2012 Sep;27(6):371-80. doi: 10.1177/1533317512454710.

Comparison of clinical characteristics between familial and non-familial early onset Alzheimer's disease

Karve SJ, Ringman JM, Lee AS, Juarez KO, Mendez MF.

J Neurol. 2012 Oct;259(10):2182-8. doi: 10.1007/s00415-012-6481-y. Epub 2012 Mar 30.

Autosomal dominant Alzheimer's disease with early frontal lobe involvement associated with the Met239Ile mutation of Presenilin 2 gene

Testi S, Fabrizi GM, Pompanin S, Cagnin A.

J Alzheimers Dis. 2012;31(1):7-11. doi: 10.3233/JAD-2012-120280.

Phenotypic profile of early-onset familial Alzheimer's disease caused by presenilin-1 E280A mutation

Sepulveda-Falla D, Glatzel M, Lopera F.

J Alzheimers Dis. 2012;32(1):1-12. doi: 10.3233/JAD-2012-120907.

Differential putaminal morphology in Huntington's disease, frontotemporal dementia and Alzheimer's disease

Looi JC, Rajagopalan P, Walterfang M, Madsen SK, Thompson PM, Macfarlane MD, Ching C, Chua P, Velakoulis D.

Aust N Z J Psychiatry. 2012 Dec;46(12):1145-58. doi: 10.1177/0004867412457224. Epub 2012 Sep 18.

N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease

Olivares D, Deshpande VK, Shi Y, Lahiri DK, Greig NH, Rogers JT, Huang X.

Curr Alzheimer Res. 2012 Jul;9(6):746-58. doi: 10.2174/156720512801322564.

Mild cognitive impairment associated with underlying Alzheimer's disease versus Lewy body disease

Boeve BF.

Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S41-4. doi: 10.1016/S1353-8020(11)70015-3.

Immunopathogenesis of neurodegenerative diseases: current therapeutic models of neuroprotection with special reference to natural products

Magrone T, Marzulli G, Jirillo E.

Curr Pharm Des. 2012;18(1):34-42. doi: 10.2174/138161212798919057.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias